Sumida, Tomokazu http://orcid.org/0000-0002-9806-2642
Lincoln, Matthew R.
Ukeje, Chinonso M.
Rodriguez, Donald M.
Akazawa, Hiroshi
Noda, Tetsuo
Naito, Atsuhiko T.
Komuro, Issei
Dominguez-Villar, Margarita
Hafler, David A.
Article History
Received: 22 November 2017
Accepted: 11 September 2018
First Online: 29 October 2018
Change Date: 7 June 2019
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Competing interests
: D.A.H. has consulted for the following companies: Bayer Pharmaceuticals, Biohaven Pharmaceuticals, Bristol Myers Squibb, Compass Therapeutics, Eisai Pharmaceuticals, EMD Serono, Genentech, Juno Therapeutics, McKinsey & Co., MedImmune/AstraZeneca, Mylan, Pharmaceuticals, Neurophage Pharmaceuticals, NKT Therapeutics, Novartis Pharmaceuticals, Proclara Biosciences, Questcor Pharmaceuticals, Roche, Sage Therapeutics, Sanofi Genzyme, Toray Industries, and Versant Venture.